Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
BackgroundThe therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone a...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.695410/full |
| _version_ | 1818594681747931136 |
|---|---|
| author | Yu-Chin Hung Jyh-Pyng Gau Jyh-Pyng Gau Shang-Yi Huang Bor-Sheng Ko Bor-Sheng Ko Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng |
| author_facet | Yu-Chin Hung Jyh-Pyng Gau Jyh-Pyng Gau Shang-Yi Huang Bor-Sheng Ko Bor-Sheng Ko Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng |
| author_sort | Yu-Chin Hung |
| collection | DOAJ |
| description | BackgroundThe therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone alone. However, the real-world effectiveness of Pom/Dex in these patients in Taiwan remains unclear.MethodsThis multicenter, registry-based study retrospectively reviewed the medical records of 49 consecutive patients undergoing Pom/Dex treatment for RRMM. We investigated the overall response rate (ORR) and PFS in these patients. The patients were stratified into two groups: those who received two (n=33) and those who received more than two (n=16) prior lines of treatment according to the numbers of regimens before Pom/Dex therapy. The differences in ORR and PFS between these two groups were further analyzed. We also analyzed factors attributed to disease progression.ResultsThe ORR was 47.7%, and the median PFS was 4.0 months (range, 0.1−21.1). Patients who received two prior lines of treatment had a higher ORR than those who received more than two prior lines of treatment (55.2% vs. 33.3%; p=0.045). The median PFS of these groups was 4.8 and 3.9 months, respectively (p=0.805). Primary lenalidomide refractoriness reduced the risk of myeloma progression following Pom/Dex treatment (hazard ratio, 0.14; p=0.001).ConclusionsThe median PFS following Pom/Dex treatment in Taiwanese RRMM patients in a real-world setting was similar to that reported by the MM-003 trial. Primary lenalidomide refractoriness should not be an obstacle for Pom/Dex treatment in RRMM. |
| first_indexed | 2024-12-16T11:03:59Z |
| format | Article |
| id | doaj.art-45c2532c91da4c6385fdf44c07aace3f |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-16T11:03:59Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-45c2532c91da4c6385fdf44c07aace3f2022-12-21T22:33:54ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-05-011110.3389/fonc.2021.695410695410Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in TaiwanYu-Chin Hung0Jyh-Pyng Gau1Jyh-Pyng Gau2Shang-Yi Huang3Bor-Sheng Ko4Bor-Sheng Ko5Chieh-Lin Jerry Teng6Chieh-Lin Jerry Teng7Chieh-Lin Jerry Teng8Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, TaiwanDivision of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, TaiwanSchool of Medicine, National Yang Ming Chiao Tung University, Taipei, TaiwanDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDivision of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanDepartment of Hematological Oncology, National Taiwan University Cancer Center, Taipei, TaiwanDivision of Hematology/Medical Oncology, Department of Medicine, Taichung Veterans General Hospital, Taichung, TaiwanDepartment of Life Science, Tunghai University, Taichung, TaiwanSchool of Medicine, Chung Shan Medical University, Taichung, TaiwanBackgroundThe therapeutic options of relapsed or refractory multiple myeloma (RRMM) remain a challenge. The MM-003 trial demonstrated that RRMM patients treated with pomalidomide and dexamethasone (Pom/Dex) have better progression-free survival (PFS) than those treated with high-dose dexamethasone alone. However, the real-world effectiveness of Pom/Dex in these patients in Taiwan remains unclear.MethodsThis multicenter, registry-based study retrospectively reviewed the medical records of 49 consecutive patients undergoing Pom/Dex treatment for RRMM. We investigated the overall response rate (ORR) and PFS in these patients. The patients were stratified into two groups: those who received two (n=33) and those who received more than two (n=16) prior lines of treatment according to the numbers of regimens before Pom/Dex therapy. The differences in ORR and PFS between these two groups were further analyzed. We also analyzed factors attributed to disease progression.ResultsThe ORR was 47.7%, and the median PFS was 4.0 months (range, 0.1−21.1). Patients who received two prior lines of treatment had a higher ORR than those who received more than two prior lines of treatment (55.2% vs. 33.3%; p=0.045). The median PFS of these groups was 4.8 and 3.9 months, respectively (p=0.805). Primary lenalidomide refractoriness reduced the risk of myeloma progression following Pom/Dex treatment (hazard ratio, 0.14; p=0.001).ConclusionsThe median PFS following Pom/Dex treatment in Taiwanese RRMM patients in a real-world setting was similar to that reported by the MM-003 trial. Primary lenalidomide refractoriness should not be an obstacle for Pom/Dex treatment in RRMM.https://www.frontiersin.org/articles/10.3389/fonc.2021.695410/fullmultiple myelomapomalidomidetreatment responserefractoryrelapse |
| spellingShingle | Yu-Chin Hung Jyh-Pyng Gau Jyh-Pyng Gau Shang-Yi Huang Bor-Sheng Ko Bor-Sheng Ko Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng Chieh-Lin Jerry Teng Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan Frontiers in Oncology multiple myeloma pomalidomide treatment response refractory relapse |
| title | Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan |
| title_full | Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan |
| title_fullStr | Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan |
| title_full_unstemmed | Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan |
| title_short | Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan |
| title_sort | pomalidomide and dexamethasone are effective in relapsed or refractory multiple myeloma in a real life setting a multicenter retrospective study in taiwan |
| topic | multiple myeloma pomalidomide treatment response refractory relapse |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.695410/full |
| work_keys_str_mv | AT yuchinhung pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT jyhpynggau pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT jyhpynggau pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT shangyihuang pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT borshengko pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT borshengko pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT chiehlinjerryteng pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT chiehlinjerryteng pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan AT chiehlinjerryteng pomalidomideanddexamethasoneareeffectiveinrelapsedorrefractorymultiplemyelomainareallifesettingamulticenterretrospectivestudyintaiwan |